11.3 Sleep-Related Movement Disorders: RLS & PLMD

11.3 Sleep-Related Movement Disorders: RLS & PLMD

Quick Answer: Restless Legs Syndrome (RLS / Willis-Ekbom Disease) is a clinical sensorimotor disorder diagnosed by the IRLSSG URGE criteria: (U) Urge to move the legs with unpleasant sensations, (R) Rest precipitates symptoms, (G) Getting up/movement provides relief, and (E) Evening/night circadian worsening. Pathophysiology centers on central dopaminergic dysregulation driven by substantia nigra iron deficiency; iron studies are checked in everyone with clinically significant RLS, and iron is given when ferritin is ≤75 ng/mL or TSAT is below 20% (IV iron also when ferritin is 75–100 ng/mL). Alpha-2-delta ligands (gabapentin, pregabalin) are first-line therapy because dopamine agonists (pramipexole, ropinirole) carry a high risk of augmentation (paradoxical symptom escalation with earlier onset and spread to arms). Periodic Limb Movement Disorder (PLMD) requires a polysomnographic PLMS index $>15\text{ events/hr}$ in adults with sleep disturbance, but cannot be diagnosed if RLS is present.

Sleep-related movement disorders are characterized by simple, stereotyped, involuntary movements that disturb sleep onset, disrupt sleep maintenance, and degrade daytime quality of life. For the Clinical Sleep Health Specialist (CCSH), navigating iron deficiency workups, distinguishing true movement disorders from clinical mimics, managing pharmacologic augmentation, and correctly scoring polysomnographic limb activity are core clinical competencies.

---

Restless Legs Syndrome (RLS): The IRLSSG URGE Diagnostic Framework

Restless Legs Syndrome (Willis-Ekbom Disease) is fundamentally a clinical diagnosis. Objective polysomnography is not required to diagnose RLS, although it frequently reveals comorbid periodic limb movements.

The Five Essential IRLSSG Diagnostic Criteria (URGE)

To establish an unequivocal clinical diagnosis of RLS, the International Restless Legs Syndrome Study Group (IRLSSG) mandates that the patient satisfy all four cardinal criteria plus an essential exclusion criterion:

1. (U) Urge to Move: An irrepressible, overwhelming urge to move the legs, usually (though not always) accompanied by or caused by uncomfortable, unpleasant sensations (dysesthesias, paresthesias) deep within the calves, thighs, or feet. Patients describe these as crawling, creeping, pulling, itching, throbbing, or electric sensations.
2. (R) Rest or Inactivity: The urge to move and any accompanying unpleasant sensations begin or worsen during periods of rest, relaxation, or sustained inactivity, such as lying in bed, sitting in an armchair, watching television, or during prolonged automobile/airplane travel.
3. (G) Getting Up / Movement Relief: The urge to move and accompanying sensations are partially or totally relieved by voluntary physical movement (walking, pacing, stretching, leg shaking, knee bending, or vigorous massage), at least as long as the motor activity continues.
4. (E) Evening or Night: The urge to move and unpleasant sensations are worse in the evening or night than during the day, or occur exclusively in the evening and night (a true circadian oscillation tied to the nadir of core body temperature and endogenous dopamine tone).
5. (Exclusion of Mimics): The occurrence of the above symptoms must not be solely accounted for by primary medical, vascular, or musculoskeletal conditions, such as:
   • Nocturnal Leg Cramps: Characterized by painful, visible, palpable, involuntary spasmodic muscle contractions (sudden hardening of the gastrocnemius), usually unilateral, lacking circadian urge, and relieved by passive muscle stretch rather than active walking.
   • Positional Discomfort / Habitual Foot Tapping: Alleviated immediately by a simple posture shift without a relentless urge to move.
   • Peripheral Neuropathy: Sensory burning and numbness persist continuously throughout the day without selective rest-induced aggravation or prompt relief upon walking.
   • Venous Stasis / Edema: Relieved by leg elevation; accompanied by dependent pitting edema and stasis dermatitis.

---

Neurobiology & Iron Metabolism in RLS

Decades of neuroimaging, autopsy, and biochemical studies demonstrate that RLS is fundamentally driven by central nervous system iron deficiency localized within the substantia nigra and striatum, resulting in secondary dysfunction of central dopaminergic pathways.

The Iron-Dopamine Axis

• Tyrosine Hydroxylase Dependency: The rate-limiting enzyme in dopamine biosynthesis, tyrosine hydroxylase, requires ferrous iron ($\text{Fe}^{2+}$) as an essential cofactor to convert L-tyrosine into L-DOPA. Central iron deficiency impairs dopamine synthesis.
• Dopamine D2 Receptor Downregulation: Hypo-ferric states in the brainstem downregulate dopamine $D_2$ and $D_3$ receptors, resulting in hyper-dopaminergic presynaptic drive paired with blunted postsynaptic signaling. This destabilizes spinal descending dopaminergic inhibitory pathways (diencephalic A11 cell group projecting to the spinal cord), releasing spinal motor reflexes and sensory gating.
• Endothelial Transferrin Receptor Dysfunction: In RLS patients, blood-brain barrier microvascular endothelial cells exhibit impaired transferrin receptor regulation, leading to insufficient iron transport into the cerebrospinal fluid and brain parenchyma, even when peripheral systemic iron stores appear borderline normal.

Laboratory Workup: Serum Ferritin & Transferrin Saturation (TSAT)

Because routine complete blood count (CBC) and serum iron can be normal in early or isolated central iron depletion, all patients presenting with RLS must undergo a dedicated morning fasting iron panel:

• Serum Ferritin: An acute-phase reactant reflecting total cellular iron storage.
• Transferrin Saturation (TSAT): Measures iron immediately available for erythropoiesis ($\text{TSAT} = [\text{Serum Iron} / \text{TIBC}] \times 100\%$).

Clinical Intervention Thresholds (AASM 2024 Guideline)

• Testing: check serum ferritin and transferrin saturation (TSAT) in everyone with clinically significant RLS, ideally in the morning after avoiding iron-containing supplements and foods for at least 24 hours, and repeat periodically.
• When to give iron (adults): oral or IV iron if ferritin ≤75 ng/mL or TSAT <20%; IV iron only if ferritin is 75–100 ng/mL. These thresholds are higher than the general-population definition of iron deficiency.
• Children: iron is started when ferritin is below 50 ng/mL.
• Oral iron: ferrous sulfate is conditionally recommended, commonly 325 mg (65 mg elemental iron) taken with vitamin C on an empty stomach; alternate-day dosing may improve absorption by limiting the rise in hepcidin, which blocks intestinal iron uptake.
• IV iron: ferric carboxymaltose is strongly recommended for adults with appropriate iron status, and low-molecular-weight iron dextran and ferumoxytol are conditionally recommended. IV iron bypasses the gut and helps patients who cannot absorb or tolerate oral iron.

The prescriber orders the labs and the iron. The CCSH explains why a "normal" ferritin on a lab report can still be too low for RLS and reinforces dosing, timing and follow-up testing.

Pharmacotherapy & The Augmentation Phenomenon

Guidance from the American Academy of Sleep Medicine (AASM) and the International Restless Legs Syndrome Study Group has shifted sharply on long-term drug treatment. The AASM's 2024 guideline strongly recommends gabapentin enacarbil, gabapentin, pregabalin and IV ferric carboxymaltose; conditionally recommends against the standard use of pramipexole, ropinirole, rotigotine and levodopa because of augmentation; conditionally recommends extended-release oxycodone and other opioids, dipyridamole and bilateral high-frequency peripheral nerve stimulation in selected patients; and recommends against cabergoline, bupropion, carbamazepine, clonazepam, valerian and valproic acid.

1. First-Line Guideline Therapy: Alpha-2-Delta Calcium Channel Ligands

• Agents: Gabapentin, Pregabalin, and Gabapentin enacarbil (a prodrug offering predictable, high-bioavailability absorption).
• Mechanism of Action: These agents bind with high affinity to the auxiliary $\alpha_2\delta-1$ and $\alpha_2\delta-2$ subunits of presynaptic voltage-gated calcium channels in the spinal cord and dorsal horn. This blunts calcium influx, suppressing the exocytotic release of excitatory neurotransmitters including glutamate, substance P, and calcitonin gene-related peptide (CGRP).
• Clinical Advantages:
  • Highly effective in relieving sensory dysesthesias and motor restlessness.
  • Enhances slow-wave sleep (Stage N3) and consolidates sleep continuity.
  • Carries a negligible risk of dopaminergic augmentation.
• Adverse Effects: Somnolence, dizziness, unsteadiness, peripheral edema, and weight gain. Requires dose titration and renal function monitoring.

2. Dopamine Agonists & The Augmentation Crisis

Non-ergot dopamine agonists—pramipexole, ropinirole, and the transdermal rotigotine patch—directly stimulate dopamine $D_2$ and $D_3$ receptors. While historically used as first-line agents due to rapid, dramatic symptom relief, they are now relegated to second-line or short-term use due to the high risk of augmentation.

Defining Augmentation

Augmentation is a paradoxical, medication-induced iatrogenic worsening of RLS symptoms caused by chronic dopaminergic overstimulation. Over time, continuous dopamine agonist exposure induces severe downregulation and desensitization of postsynaptic dopamine receptors and hyper-sensitizes spinal motor circuits.

• Clinical Hallmarks of Augmentation:
  1. Earlier Daily Onset: Symptoms begin progressively earlier in the day (e.g., shifting from 10:00 PM to 4:00 PM, and eventually to noon or morning).
  2. Anatomical Expansion: Symptoms expand beyond the lower extremities, spreading rostrally to involve the arms, hands, and trunk.
  3. Shorter Rest Latency: The latency from sitting down or resting to symptom onset decreases from hours to minutes or seconds.
  4. Increased Symptom Intensity: Dysesthesias become far more intense, severe, and distressing.
  5. Paradoxical Dose Escalation Failure: Increasing the dopamine agonist dose provides only brief, fleeting relief followed by even more severe symptom escalation weeks later.

Augmentation Management Protocol

1. Check morning serum ferritin and TSAT and replete iron according to the thresholds above.
2. Avoid further dose increases of the dopamine agonist.
3. Slowly and gradually taper the dopamine agonist downward over several weeks to avoid severe acute dopamine agonist withdrawal syndrome (DAWS).
4. Initiate and cross-titrate an alpha-2-delta ligand (gabapentin or pregabalin).
5. For severe, refractory augmentation failing alpha-2-delta therapy, low-dose opioids (oxycodone, methadone, or buprenorphine) provide potent, stable relief under specialized clinical supervision.

---

Periodic Limb Movement Disorder (PLMD) vs. PLMS

It is clinically imperative to distinguish the polysomnographic finding of Periodic Limb Movements in Sleep (PLMS) from the formal clinical diagnostic entity of Periodic Limb Movement Disorder (PLMD).

AASM Scoring Rules for PLMS

On nocturnal polysomnography, limb movements are monitored via surface electromyography (EMG) placed longitudinally over the anterior tibialis muscle of each leg.

• Individual Movement Duration: The EMG burst must last between $0.5\text{ and } 10.0\text{ seconds}$.
• Amplitude Threshold: The EMG signal must demonstrate an amplitude increase of at least $8\mu\text{V}$ above resting baseline.
• Inter-Movement Interval: The interval between the onset of one movement and the onset of the consecutive movement must be between $5\text{ and } 90\text{ seconds}$.
• Periodic Movement Series: A sequence of at least 4 consecutive movements meeting duration and interval criteria is required to define a PLMS series.
• PLMS Associated with Arousals (PLMA): Scored when an EEG arousal begins concurrently with, or within $0.5\text{ seconds}$ before or after, the limb movement burst.

$\text{PLMS Index (PLMI)} = \frac{\text{Total Scored PLMS}}{\text{Total Sleep Time (TST) in hours}}$

$\text{PLM Arousal Index (PLMAI)} = \frac{\text{Total PLMS Associated with Arousals}}{\text{Total Sleep Time (TST) in hours}}$

Diagnostic Criteria for PLMD (ICSD-3)

To render a formal diagnosis of Periodic Limb Movement Disorder (PLMD), all of the following criteria must be met:

1. Objective polysomnography demonstrates a $\text{PLMS Index} > 15\text{ events/hour}$ in adults (or $>5\text{ events/hour}$ in children).
2. The patient exhibits clinical insomnia, fragmented sleep, or daytime fatigue/sleepiness attributable to the movements.
3. CRITICAL MUTUAL EXCLUSIVITY RULE: The PLMS and sleep disturbance are NOT better explained by another primary sleep disorder:
   • RLS: Over $80\%$ to $90\%$ of patients with Restless Legs Syndrome exhibit an elevated PLMI on PSG. However, when RLS is present, the diagnosis is coded as RLS with PLMS, and PLMD is strictly excluded!
   • Narcolepsy, OSA, or Medication Effects: If the movements occur exclusively following obstructive apneas/hypopneas, during active narcolepsy, or secondary to antidepressant therapy (SSRIs, SNRIs), PLMD cannot be diagnosed.

---

Sleep-Related Bruxism

Sleep-Related Bruxism is a sleep-related movement disorder characterized by repetitive or sustained rhythmic (phasic) or non-rhythmic (tonic) masticatory muscle contractions (clenching or grinding of teeth) during sleep.

• Pathophysiology: Centrally mediated autonomic arousals that activate trigeminal motor neurons, commonly emerging during Stage N1 and N2 sleep.
• Polysomnographic Scoring: Monitored via masseter and temporalis surface EMG channels:
  • Phasic bursts: At least 3 rhythmic EMG bursts lasting $0.25$ to $2.0$ seconds.
  • Tonic bursts: Continuous sustained clenching lasting $>2.0$ seconds.
• Clinical Manifestations: Severe tooth wear and dental attrition, fractured enamel or restorations, jaw muscle hypertrophy, temporal morning headaches, and temporomandibular joint (TMJ) arthralgia.
• Management: Custom-fabricated hard acrylic occlusal splints (nightguards) to protect dentition from mechanical trauma; botulinum toxin injections into masseter muscles for refractory muscular pain; and behavioral stress reduction.

---

Differential Diagnosis of Nocturnal Lower Extremity Symptoms